Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Tesaro Inc. : TESARO Details Niraparib Phase 1 Clinical Data Presented at the 2013 ASCO Annual Meeting

06/04/2013 | 11:12am US/Eastern
Recommend:
0
  • A RECIST Response Rate of 75% Was Achieved at the 300mg Dose in Patients With Platinum-Sensitive High Grade Serous Ovarian Cancer
  • A RECIST Response Rate of 50% Was Achieved Across All Dose Levels in Patients With Platinum Sensitive Ovarian Cancer and Germline BRCA Mutations
  • Progression Free Survival Exceeded One Year Among Platinum-Sensitive Ovarian Cancer Responders, Independent of BRCA Mutation Status

CHICAGO, June 4, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that final results from a Phase 1 trial of niraparib, an inhibitor of poly ADP-ribose polymerase (PARP), were presented this morning at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

At a dose of 300 milligrams once daily, which represents the dose and schedule that will be utilized in the Phase 3 studies, 75% (three of four patients) with platinum sensitive high grade serous ovarian cancer (HGSOC) achieved a RECIST response. Across all dose levels (30 milligrams to 400 milligrams daily), a RECIST response rate of 46% (6/13 patients) was observed in this population. A RECIST response rate of 50% (5/10 patients) was achieved in patients with platinum sensitive ovarian cancer and germline BRCA mutations. The median duration of response was 431 days for platinum sensitive germline BRCA patients and 444 days for platinum sensitive patients who were not germline BRCA mutation carriers.

In addition, 50% (two of the four patients) with BRCA-positive breast cancer achieved a response. Of the 10 patients with prostate cancer who had evaluable circulating tumor cell count (CTC) levels, seven (70%) had a reduction of > 30% in CTC count.

The ovarian cancer patients enrolled in this study had received a median of six previous regimens of systemic therapy. The breast cancer patients enrolled in this study had received a median of five previous regimens of systemic therapy.

Pharmacokinetic parameters were dose proportional and support once per day oral dosing of niraparib. Niraparib was generally well tolerated at 300 milligrams daily, with a low rate of grade 3/4 toxicities. Thrombocytopenia was identified as the dose-limiting toxicity at a daily dose level of 400 milligrams. The most frequently observed adverse events at the 300 milligram dose included grade 1/2 anemia, fatigue and nausea.   

"We are very pleased with the RECIST response rates observed in both ovarian and breast cancer patients in this trial, particularly at the 300 milligrams once daily dose that will be evaluated in our Phase 3 program," said Dr. Mary Lynne Hedley, President of TESARO. "The results of this study provide further support for the design of our planned Phase 3 trials in ovarian and breast cancer and, in particular, the potential utility of platinum sensitivity and BRCA status as predictors of response to niraparib."

Phase 1 Study Design

This Phase 1 study was designed as a two part trial to determine the maximum tolerated dose and evaluate preliminary antitumor activity, safety/tolerability, pharmacokinetic and pharmacodynamic properties of niraparib. Part A enrolled 60 patients who received a single daily dose of 30 to 400 milligrams of niraparib. Following identification of the maximum tolerated dose, Part B of the study enrolled an additional 40 patients with platinum resistant high grade serous ovarian cancer or castration-resistant prostate cancer who received a single daily dose of 300 milligrams of niraparib. Preliminary results of this study were presented at the ASCO annual meeting in 2011.

About TESARO

TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics. For more information, visit www.tesarobio.com.

To the extent that statements contained in this press release are not descriptions of historical facts regarding TESARO, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the initiation of future clinical trials, availability of data from ongoing clinical trials, expectations for regulatory approvals, and other matters that could affect the availability or commercial potential of our drug candidates. Niraparib is an investigational agent and, as such, has not been approved by any regulatory agencies.TESARO undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see TESARO's Form 10-K for the year ended December 31, 2012.

CONTACT: Investor/Media Contact:

         Jennifer Davis

         Sr. Director, Corporate Development & Investor Relations

         +1.781.325.1116 or jdavis@tesarobio.com
distributed by
Recommend :
0
React to this article
Latest news
Date Title
6m ago LEICESTER CITY V MANCHESTER UNITED : Preview and Projected Lineups
9m ago AKSA AKRILIK KIMYA SANAYII : Arson in broad daylight: Part Two
11m ago NATIONAL SECURITY : Minister says Non-Ghanaians should not compete with Ghanaians for work
11m ago TAKORADI : Local content in oil sector to be implemented
11m ago VODAFONE : Ghana to launch programme for the youth
15m ago EVERSENDAI BHD : Face to face: Tan Sri A.K. Nathan, Eversendai
20m ago RICOH : hammer Coca-Cola to keep Cummins tryless in Japan (Rugby)
23m ago LINK REAL ESTATE INVESTMENT : Lok Fu Plaza Introduces Special Halloween-themed Food Visitors to Lok Fu Plaza Dark Mansion can get their fill of fear and food
30m ago HOME DEPOT : 5 ways to protect yourself from data breaches
32m ago STANDARD CHARTERED : to organise its Second UAE National Job Fair
Latest news
Advertisement
Hot News 
BANCO ESPIRITO SANTO : Swiss begin bankruptcy proceedings against Espirito Santo private bank
DIXONS CARPHONE : Phones 4U says Vodafone will take 140 of its stores
EREDENE CAPITAL : Sells Aboyne To Brick Eagle For GBP3 Million
ITT EDUCATIONAL SERVICES : Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
SINGULUS TECHNOLOGIES : Sees Weak 2014
Most Read News
1d ago ORACLE : When music stops for Oracle CEO dance, Catz may grab Ellison's chair - Analysts
1d ago DTF TAX FREE INCOME : Duff & Phelps Closed-End Funds Announce Dividends
1d ago BANK OF AMERICA : Merrill Lynch fires brokers for promoting outside hedge fund - source
1h ago AIR FRANCE KLM : pilots extend strike until Sept. 26
1d ago BOEING : U.N. aviation body to mull space safety as space taxis ready for flight
Most recommended articles
41m ago EU mulls tapping unused rescue funds to boost investment - paper
44m agoDJNew Zealand Prime Minister John Key Wins Third Term -- Update
57m ago Canada Fin Min says G20 near growth target, wants more from Europe
58m ago RHEINMETALL : German defense industry threatens to move production abroad
1h agoDJNew Zealand Election Sees Prime Minister John Key Win Third Term
Dynamic quotes  
ON
| OFF